ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle

This study has been completed.

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00671320
  Purpose

To determine whether valdecoxib 40 mg twice a day the first day and then 40mg once a day until Day 7, was at least as effective as diclofenac 75 mg twice a day for 7 days, in treating acute first or second degree ankle sprain. The study also compared valdecoxib and diclofenac with respect to time to onset of pain relief (measured after the first dose), tolerability (adverse events) and time to return to Normal Function/Activity, among other measures.


Condition Intervention Phase
Pain
Sprains and Strains
Sprain
Drug: valdecoxib
Drug: diclofenac
Phase IV

MedlinePlus related topics:   Ankle Injuries and Disorders   

ChemIDplus related topics:   Valdecoxib    Diclofenac    Diclofenac potassium    Diclofenac sodium   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:   A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib Vs. Diclofenac In Ankle Sprain

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Patient's assessment of ankle pain VAS [ Time Frame: Day 4 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to onset of pain relief [ Time Frame: 0, 15, 30, 45, and 60 minutes after first dose ] [ Designated as safety issue: No ]
  • Physician's global assessment of ankle injury [ Time Frame: Days 1, 4, and 7 ] [ Designated as safety issue: No ]
  • Patient's global assessment of ankle injury [ Time Frame: Days 1, 4 and 7 ] [ Designated as safety issue: No ]
  • Patient's assessment of normal function/activity [ Time Frame: Days 1 to 7 ] [ Designated as safety issue: No ]
  • Patient's and physician's satisfaction assessments [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
  • Patient's assessment of ankle pain on visual analogue scale (VAS) [ Time Frame: Days 1 to 7 ] [ Designated as safety issue: No ]

Enrollment:   202
Study Start Date:   December 2002
Study Completion Date:   October 2003

Arms Assigned Interventions
Arm 1: Active Comparator Drug: valdecoxib
valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
Arm 2: Active Comparator Drug: diclofenac
diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients had sprained their ankle within 48 hours
  • The sprain was a first or second degree ankle sprain of the lateral aspect, specifically: anterior talofibular ligament and/or calcaneofibular ligament
  • At presentation patients were to have had moderate-severe ankle pain, (i.e., patient's assessment of ankle pain, on full weight bearing, using a 100 mm visual analog scale (VAS) was ≥ 45 mm), have a minimum rating of 2 on the Patient's Global Assessment of Ankle Injury and Patient's Assessment of Normal Function/Activity
  • Investigator must have thought that the patient required and was eligible for therapy with an anti-inflammatory agent and/or analgesic to control symptoms

Exclusion Criteria:

  • Women who were not post-menopausal or surgically sterilized, or who had have a positive urine pregnancy test prior to randomization and/or were not using adequate contraception according to the judgment of the Investigator
  • Patients with a similar injury of the same joint within the last 6 months
  • Clinical evidence of complete rupture of ankle ligaments (third degree sprain), required bed rest, hospitalization, surgical intervention for the ankle injury or non-removable full cast, bilateral occurrence of ankle injury or ankle and knee injury on the same side
  • Patients with esophageal, gastric or duodenal ulcer within 30 days prior to randomization or had active GI or other disease that in the opinion of the investigator would preclude safe participation by the subject in the study.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00671320

Locations
Argentina
Pfizer Investigational Site    
      Buenos Aires, Argentina
Argentina, Buenos Aires
Pfizer Investigational Site    
      Avellaneda, Buenos Aires, Argentina, 1872
Pfizer Investigational Site    
      San Isidro, Buenos Aires, Argentina, 1642
Chile
Pfizer Investigational Site    
      Santiago, Chile
Chile, RM
Pfizer Investigational Site    
      Santiago, RM, Chile
Colombia, Antioquia
Pfizer Investigational Site    
      Medellin, Antioquia, Colombia, (574) 5141516
Colombia, Cundinamarca
Pfizer Investigational Site    
      Bogota, Cundinamarca, Colombia, (57) 310-2322198
Pfizer Investigational Site    
      Bogota, Cundinamarca, Colombia, (57) 310-8849622
Colombia, Cundinarmarca
Pfizer Investigational Site    
      Bogota, Cundinarmarca, Colombia, (571) 6 164278
Colombia, Santander
Pfizer Investigational Site    
      Bucaramanga, Santander, Colombia, (577) 6 395409
Colombia, Valle del Cauca
Pfizer Investigational Site    
      Calli, Valle del Cauca, Colombia, (57) 310-8259712
Pfizer Investigational Site    
      Cali, Valle del Cauca, Colombia, (57) 315-5410469
Mexico, Nuevo Leon
Pfizer Investigational Site    
      Monterrey, Nuevo Leon, Mexico, 64460
Peru
Pfizer Investigational Site    
      Lima, Peru, 27
Pfizer Investigational Site    
      Lima, Peru

Sponsors and Collaborators
Pfizer

Investigators
Study Director:     Pfizer CT.gov Call Center     Pfizer    
  More Information


To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site
 
Link to ClinicalStudyResults.org posting:  This link exits the ClinicalTrials.gov site
 

Responsible Party:   Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:   VALA-0513-146, A3471037
First Received:   March 31, 2008
Last Updated:   April 30, 2008
ClinicalTrials.gov Identifier:   NCT00671320
Health Authority:   Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Keywords provided by Pfizer:
acute ankle sprain, acute pain, South America  

Study placed in the following topic categories:
Wounds and Injuries
Diclofenac
Disorders of Environmental Origin
Pain
Valdecoxib
Sprains and Strains

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Peripheral Nervous System Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers